A list of puns related to "Regeneron Pharmaceuticals"
Overview
Regeneron Pharmaceuticals, Inc., a biotech company that develops and commercializes medicines for treating various medical conditions worldwide. Its pipeline of products include: EYLEA injection that treats several edemas; Dupixent injection to treat atopic dermatitis and asthma in adults; Praluent injection for clinical atherosclerotic cardiovascular disease in adults; Kevzara solution for treating rheumatoid arthritis in adults; Libtayo injection to treat locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes; ZALTRAP injection to treat metastatic colorectal cancer.
The point is that REGN has a strong and diversified pipeline of products.
Meanwhile, REGN is also developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech
Fundamentals
Despite operating in unprecedented circumstances of a global pandemic, REGN delivered strong commercial and financial results. For the full year 2020, Regeneron grew revenues by 30% and earnings by 28%, with an increasingly diversified set of revenue and earnings streams. In fact, more than 80% of revenue growth came from products and revenues, other than EYLEA. Also, the company discovered and developed a novel antibody cocktail against COVID-19 known as REGEN-COV. Most recently, the company showed promising data suggesting that REGEN-COV reduces transmission of the virus and prevents infections in patients at high risk of contracting the virus. With that discovery, a new supply agreement was established with the United States government for an additional 1.25 million treatment doses for up to $2.6 billion.
Technicals
Although REGN price rose 34% in 2020, in the last 2 quarters it decreased nearly 20% from its 664$ peak in July 2020. While REGN's price reached its 6-month bottom at 477$, the company continued to perform extremely well amid the complicated situation of the pandemic. RSI(14) level points to 44.57 which indic
... keep reading on reddit ➡There have been reports that Remdesivir may negatively impact liver and kidney functions. The fact that they are giving him this treatment knowing the potential negative effects makes me think that he is not just having 'mild' symptoms.
Hallo,
https://twitter.com/WarlusTrades/status/1330303480410599426
Hier weitere Informationen zu der Firma:
https://www.deraktionaer.de/artikel/pharma-biotech/corona-hoffnung-regeneron-trump-cocktail-zeigt-wirkung-20219767.html
Ohne Gewähr ;-)
LG
siggi
Gerade gesehen, das hängt wohl mit dieser aktuellen Nachricht zusammen:
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19?utm_medium=email&utm_source=govdelivery
> Die FDA genehmigt monoklonale Antikörper zur Behandlung von COVID-19
Mal sehen, was die Aktie am Montag macht.
Regeneron Pharmaceuticals Inc. has found itself in the spotlight after President Donald Trump was treated with the company’s experimental antibody treatment for Covid-19, just days after the unveiling of promising preliminary trial results.
https://www.google.co.uk/amp/s/www.bloomberg.com/amp/news/articles/2020-10-02/trump-treatment-thrusts-regeneron-virus-drug-to-center-stage
I read an article that regeneron will work with the FDA to lift the hold on their cancer treatment drug, anyone know or think how long this could take? This could get the stock soaring from about $500 to at least $600 as we’ve seen in the past with this stock.
Overview
Regeneron Pharmaceuticals, Inc., a biotech company that develops and commercializes medicines for treating various medical conditions worldwide. Its pipeline of products include: EYLEA injection that treats several edemas; Dupixent injection to treat atopic dermatitis and asthma in adults; Praluent injection for clinical atherosclerotic cardiovascular disease in adults; Kevzara solution for treating rheumatoid arthritis in adults; Libtayo injection to treat locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes; ZALTRAP injection to treat metastatic colorectal cancer.
The point is that REGN has a strong and diversified pipeline of products.
Meanwhile, REGN is also developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech
Fundamentals
Despite operating in unprecedented circumstances of a global pandemic, REGN delivered strong commercial and financial results. For the full year 2020, Regeneron grew revenues by 30% and earnings by 28%, with an increasingly diversified set of revenue and earnings streams. In fact, more than 80% of revenue growth came from products and revenues, other than EYLEA. Also, the company discovered and developed a novel antibody cocktail against COVID-19 known as REGEN-COV. Most recently, the company showed promising data suggesting that REGEN-COV reduces transmission of the virus and prevents infections in patients at high risk of contracting the virus. With that discovery, a new supply agreement was established with the United States government for an additional 1.25 million treatment doses for up to $2.6 billion.
Technicals
Although REGN price rose 34% in 2020, in the last 2 quarters it decreased nearly 20% from its 664$ peak in July 2020. While REGN's price reached its 6-month bottom at 477$, the company continued to perform extremely well amid the complicated situation of the pandemic. RSI(14) level points to 44.57 which indicates
... keep reading on reddit ➡Overview
Regeneron Pharmaceuticals, Inc., a biotech company that develops and commercializes medicines for treating various medical conditions worldwide. Its pipeline of products include: EYLEA injection that treats several edemas; Dupixent injection to treat atopic dermatitis and asthma in adults; Praluent injection for clinical atherosclerotic cardiovascular disease in adults; Kevzara solution for treating rheumatoid arthritis in adults; Libtayo injection to treat locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes; ZALTRAP injection to treat metastatic colorectal cancer.
The point is that REGN has a strong and diversified pipeline of products.
Meanwhile, REGN is also developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech
Fundamentals
Despite operating in unprecedented circumstances of a global pandemic, REGN delivered strong commercial and financial results. For the full year 2020, Regeneron grew revenues by 30% and earnings by 28%, with an increasingly diversified set of revenue and earnings streams. In fact, more than 80% of revenue growth came from products and revenues, other than EYLEA. Also, the company discovered and developed a novel antibody cocktail against COVID-19 known as REGEN-COV. Most recently, the company showed promising data suggesting that REGEN-COV reduces transmission of the virus and prevents infections in patients at high risk of contracting the virus. With that discovery, a new supply agreement was established with the United States government for an additional 1.25 million treatment doses for up to $2.6 billion.
Technicals
Although REGN price rose 34% in 2020, in the last 2 quarters it decreased nearly 20% from its 664$ peak in July 2020. While REGN's price reached its 6-month bottom at 477$, the company continued to perform extremely well amid the complicated situation of the pandemic. RSI(14) level points to 44.57 which indic
... keep reading on reddit ➡Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.